Welcome To Marksans Pharma Ltd

An Indian pharmaceutical company having a global footprint Our strengths lie in research, manufacturing and marketing of finished dosage pharmaceutical formulations.

Know More
300
Products
50
Markets Served
2000
Employees
1500
SKUs

Welcome To Marksans Pharma Ltd

An Indian pharmaceutical company having a global footprint Our strengths lie in research, manufacturing and marketing of finished dosage pharmaceutical formulations.

Know More
300
Products
50
Markets Served
2000
Employees
1500
SKUs

Health & Wellness

Consumer Self-Care Products - OTC

Pain Management

Upper Respiratory

Digestive Health

VMS (Vitamins Minerals and Supplements)

Skin Care Product

Prescription – Rx Therapeutic Segments

Cardiovascular System (CVS)

Central Nervous System (CNS)

Oncology

Anti-Diabetics

Anti Biotic

Global Presence

In keeping with its mission towards global well-being, Marksans Pharma continues to enter into strategic partnerships with key players around the globe.
These collaborative efforts help to deliver quality and timely pharmaceutical solutions across markets worldwide.
Moving forward, Marksans Pharma believes in strengthening current partnerships while entering into new strategic alliances for
innovative solutions in the ever-evolving healthcare sector.

Investor Relations

At Marksans Pharma, we believe in transparency and honest communication with all our stakeholders.
We are committed to bringing the same level of integrity to our investors as we do to the pharmaceutical industry.
Here, you can find ample financial reports for key insights into our performance, growth, and earnings

General Information & Investor Contact

General Information & Investor Contact
Corporate Announcements

Corporate Announcements
Financial Results

Financial Results
Compliances

Compliances
Press Release

Press Release
ESG Profile

ESG Profile

Media

Marksans Pharma Limited’s wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483’s were issued during the Audit.
Marksans Pharma Limited’s wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483’s were issued during the Audit.
Marksans Pharma Limited’s wholly owned subsidiary Relonchem Limited has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.
View all
Marksans Pharma Limited’s wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483’s were issued during the Audit.
Marksans Pharma Limited’s wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483’s were issued during the Audit.
Marksans Pharma Limited’s wholly owned subsidiary Relonchem Limited has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.
View all
Corporate Social
Responsibility
Sustainability at the Core: Our Pledge to Social and Environmental Responsibility
Read More